Altered expression of costimulatory molecules in dementias

Stefan Busse1 · Franz von Hoff1 · Enrico Michler1 · Roland Hartig2 · Bernhard Bogerts1 · Mandy Busse1,3

Received: 28 November 2020 / Accepted: 4 July 2021 / Published online: 24 August 2021
© The Author(s) 2021

Abstract
Although the expression of co-stimulatory molecules plays an important role in the immune system, only little is known about their regulation in dementias. Therefore, we determined the expression of CD28, ICOS (CD278) and CTLA-4 (CD152) by CD4+ and CD8+ T cells in the peripheral blood of patients with mild cognitive impairment (MCI; \( N = 19 \)), Alzheimer’s disease (AD; \( N = 51 \)), vascular dementia (VD; \( N = 21 \)) and frontotemporal dementia (FTD; \( N = 6 \)) at the point in time of diagnosis compared to 19 non-demented elderly persons. The expression of CD28 and ICOS by CD4+ and CD8+ T cells was not changed in AD, FTD or VD patients. The expression of the negative regulator CTLA-4 was increased by CD4+ T cells from AD and FTD patients and by CD8+ T cells from VD patients. The classification of the AD patients according to the severity of the disorder showed stage-dependent alterations of CD28, ICOS and CTLA-4 expression. In AD patients, the correlation analysis showed an association between the decline in CD28+ T cells and the increase in CTLA-4+ T cells with cognitive decline, measured by the mini-mental state examination (MMSE), tau proteins and Amyloid-β, important AD biomarkers in cerebrospinal fluid (CSF). In FTD patients, a positive association between Q Albumin, a marker for blood-CSF-barrier function, and CD28 and a negative correlation between Q Albumin and ICOS expression were determined. Our data suggest a dysregulated balance between the expression of negative and positive co-stimulatory molecules by T cells in AD patients, which might contribute to chronic inflammation observed in dementia.

Keywords Alzheimer’s disease · Vascular dementia · Frontotemporal dementia · T cells · Costimulation

Introduction
In our aging population, the prevalence of dementia is increasing. In 2010, approximately 35.6 million people worldwide suffered from dementia, a number which is expected to triple by the year 2050. Each year, 7.7 million people were newly diagnosed with dementia worldwide. The most prevalent cause of dementia is Alzheimer’s disease (AD). Besides, vascular dementia (VD) and frontotemporal dementia (FTD) contribute to the loss of cognitive functions and behavioural changes in elderly people [1–4]. In AD, Amyloid-β1-42, and tau proteins are established core cerebrospinal biomarkers [3]. FTD is a heterogeneous neurodegenerative disorder with some symptoms overlap with AD [5]. Some FTD forms are tauopathies, they are caused by a loss of tau protein expression [6]. VD has multifactorial causes, but vascular components such as atherosclerosis, (micro)infarcts and amyloid angiopathy play an important role [4].

Aging is also associated with a progressive decline in immune competence of T and B lymphocytes. T cell senescence is characterized e.g. by the loss of co-stimulatory receptors such as CD28 and impairment of TCR signaling, leading to defects in classical T cell functions [7, 8]. Moreover, the term “inflamm-aging” was created to describe the presence of a chronic state of inflammation in many age-associated diseases. It is believed that inflammatory immune responses [9–11] and a dysfunction of the blood-cerebrospinal fluid (CSF)-barrier (B-CSF-B) [12, 13] are relevant in AD, FTD and VD.

During conventional T cell activation, the interaction of the T cell receptor (TCR) with MHC class I or class II-peptide complexes initiates the cascade of T cell activation.
However, an important secondary co-stimulatory signal must be delivered to promote cellular proliferation and survival following T cell activation [14]. This “second signal” is provided by the co-stimulatory molecule CD28 [15]. CD28 is a homodimeric cell surface receptor of the immunoglobulin superfamily to which also belong the co-receptor molecules cytotoxic T-lymphocyte antigen-4 (CTLA-4; CD152) and inducible T cell co-stimulator (ICOS) [16–18].

While CD28 is expressed on the majority of human CD4+ T cells but only about half of circulating CD8+ T cells, CTLA-4 is constitutively expressed on regulatory T (Treg) cells and upregulated by activated conventional T-cells and also ICOS is rapidly induced following T cell activation [16, 19]. CD28 mediated co-stimulation controls T cell responses by providing means of preventing unwanted (anti-self) and triggering wanted (antimicrobial) immunity while CTLA-4 ligation serves to mitigate this process [18].

Previously we have shown alterations in the adaptive immune system in patients suffering from AD, VD and FTD, in particular AD associated changes in the T cell naïve/memory subpopulations [20, 21]. Therefore, we wanted to determine whether also the expression of the T cell co-stimulatory markers CD28, ICOS and CTLA-4 was affected by dementia.

**Materials and methods**

**Study cohort**

The study was performed in accordance with German laws, the Declaration of Helsinki and the guidelines of the local institutional review board. Written consent was obtained from all patients and healthy volunteers. 10 ml blood tubes were collected from 19 MCI patients (14 female, 5 male; mean age 76.74 years), 51 AD patients (32 female, 19 male; mean age 80.46 years), 21 VD patients (13 female, 8 male; mean age 78.14 years) and 6 FTD patients (2 female, 4 male; mean age 74.33 years). Diagnosis was performed by psychiatrists, neurologists and psychologists according to DSM-IV criteria, based on the results obtained by magnetic resonance imaging (MRI) of the brain or cerebral computer tomography (CT), cerebrospinal fluid (CSF) analysis, mini-mental state evaluation (MMSE) and electroencephalography (EEG). CSF analysis, including levels of Amyloid-β1-40, Amyloid-β1-42, total tau, phospho-tau and Q-Albumin, was performed at the institute of clinical chemistry and pathobiochemistry of our university hospital. The levels of Amyloid-β1-40, Amyloid-β1-42, total tau, phospho-tau (\(^{32}P\)) were determined by using the INNOTEST\textsuperscript{®} immunoassays, solid-phase enzyme immunoassays (Fujirebio, Gent, Belgium). Q Albumin was measured on IMMAGE\textsuperscript{®} 800 Protein Chemistry Analyzer (Beckman Coulter). Clinicians had access to detailed clinical files, including the medical histories by proxy and referral letters from the general practitioners. The stages of AD were divided according to the results obtained from MMSE: MMSE scores 24–20: mild AD; MMSE 19–10: moderate AD; MMSE below 10: severe AD. 19 elderly non-demented persons (13 female, 6 male; mean age 71.22 years) donated blood as controls. The demographic data of our study cohort, including MMSE values and Q Albumin values, are shown in Table 1. From all patients and control individuals, routine blood analyses (including differential blood cell count, levels of C-reactive protein, glucose, lipids, liver enzymes and thyroid hormones) were performed. Abnormal routine blood values (e.g. enhanced CRP or abnormal immune cell counts), a history of severe immune diseases, immunomodulating treatment, cancer, chronic terminal disease, substance abuse or severe trauma were exclusion criteria of the study.

**Flow cytometry analysis**

50 µl EDTA-blood per tube were incubated with the primary antibodies (Abs) at room temperature (RT) for 20 min. in the dark: Fluorescein (FITC) anti-human CD4 (M-T466), VioGreen anti-human CD8 (BW135/80) VioBlue anti-human ICOS (REA192), Phycoerythrin (PE) anti-human CD28 (15E8) (all Abs from Miltenyi Biotech, Bergisch Gladbach, Germany). Afterwards, 450 µl erythrocyte lysis buffer (eBioScience, Frankfurt, Germany) was added to the tube and incubated at RT for 30 min. in the dark.

For intracellular staining of CTLA-4, the cells were washed twice using FACS buffer and the pellet was incubated with 100 µl Fix/ Perm buffer (BD Biosciences) at RT for 30 min. in the dark. Then the cells were washed twice with perm buffer and incubated with allophycocyanin (APC) anti-human CTLA-4 (BNI-3; Miltenyi Biotech, Bergisch Gladbach, Germany) at RT for 30 min. in the dark. After two washing steps, data were collected on a FACS flow cytometer (LSR Fortessa, BD Biosciences, Mountain View, CA, USA) and analyzed using FACS DIVA software 6.1.3 (BD Biosciences, Mountain View, CA, USA) and FlowJo software (TreeStar Inc., Ashland, OR, USA). The data were analyzed using biexponential transformation function for complete data visualization.

**Determination of B-CSF-B integrity**

The blood-cerebrospinal fluid (CSF)-barrier (B-CSF-B) function was calculated by quotient (Q) albumin. Therefore, the concentration of albumin was analyzed in CSF and in parallel also in serum. Q albumin was calculated by dividing the detected concentration of albumin in CSF by that detected in serum (result: Q albumin). Since normal aging is associated with a decline in B-CSF-B
functions, we calculated an age-dependent reference value of B-CSF-B in order to differentiate modifications of B-CSF-B induced by aging from disorder-related alterations.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 7. Diagnostic group differences were calculated by Kruskal–Wallis test, followed by Mann–Whitney test and Dunn’s multiple comparison test. Shapiro–Wilk normality tests were performed to analyze normal distribution. Correlation analyses were performed according to Pearson. Significance was defined as \( p < 0.05 \).

Table 1 Demographic data of the study cohort

| Characteristics         | Controls | MCI | AD Total | AD Mild | AD Moderate | AD Severe | VD | FTD |
|-------------------------|----------|-----|----------|---------|-------------|-----------|----|-----|
| Total (n)               | 19       | 19  | 51       | 13      | 26          | 12        | 21 | 6   |
| Age (years; mean)       | 71.2     | 76.7| 80.5     | 81.5    | 80.1        | 80.4      | 78.1| 74.3|
| Gender (female/male)    | 13/6     | 14/5| 32/19    | 9/4     | 14/12       | 9/3       | 13/8| 2/4 |
| MMSE (mean)             | 28.1     | 26.3| 15.3     | 21.5    | 15.5        | 7.4       | 16.7| 20.7|
| Q Albumin (mean)        | 8.2      | 10.1| 8.6      | 9.6     | 12.8        | 10.3      | 7.9 |

CSF diagnostics

|                      | AD Mild | AD Moderate | AD Severe |
|----------------------|---------|-------------|-----------|
| MMSE (mean)          | 21.54   | 15.52       | 7.36      |
| Q albumin (mean)     | 8.60    | 9.59        | 12.75     |
| Total tau (pg/ml)    | 628.3   | 701.4       | 787.7     |
| Ptau (pg/ml)         | 106.70  | 91.45       | 82.22     |
| Amyloid-β1-40 (pg/ml)| 10.690  | 9338        | 7514      |
| Amyloid-β1-42 (pg/ml)| 519.0   | 540.0       | 448.9     |

The demographic data of the study cohort including age, gender, MMSE values and Q albumin are shown in Table 1a. AD specific markers total and phospho-tau, Amyloid-β 1–40 and 1–42 obtained in cerebrospinal fluid (CSF) from patients with mild, moderate and severe AD were listed in Table 1b.

Results

Altered expression of CTLA-4 in dementias

Using flow cytometry of peripheral whole blood, we analyzed the frequency of CD4+ and CD8+ T cells and the expression of CD28, CTLA-4 and ICOS in patients suffering from AD, VD and FTD and compared them to non-demented controls. We detected in AD and in VD, but not in FTD a reduction of the percentage of CD4+ and CD8+ T cells (Suppl. Table 1). No diagnosis-dependent changes regarding the expression of CD28 and ICOS by CD4+ and CD8+ T cells were observed (Suppl. Fig. 1). However, the expression of CTLA-4 on CD4+ T cells among CD4+ T cells increased from 1% in the control group to 1.3% in AD \( (p = 0.0282) \) and 1.9% in FTD \( (p = 0.0118) \); Fig. 1a). Within the CD8+ T cell
population of VD patients, on average 0.5% CD8 + T cell co-expressed CTLA-4 compared to 0.3% CTLA-4 + CD8 + T cells in non-demented individuals \( (p = 0.0271; \text{Fig. 1b}) \).

Despite trends, no correlations were determined between the age of patients and control individuals and the frequency of CD4 T cells expressing CD28 \( (p = 0.0988) \), CTLA-4 \( (p = 0.3127) \) or ICOS \( (p = 0.4833) \) and between age and the number of CD8 + T cells expressing CD28 \( (p = 0.9272) \), CTLA-4 \( (p = 0.0644) \) or ICOS \( (p = 0.0685) \); data not shown.

**Influence of the stage of AD upon expression of costimulatory molecules**

Patients suffering from MCI show an increased risk for the development of dementia. Traditionally, MCI is regarded as the typical prodromal stages of dementia due to AD, but nonamnestic MCI might also lead to FTD or LBD [22]. AD can be subdivided according to the severity of symptoms into mild, moderate and severe AD. In several stages of AD, but not in MCI, we found diminished CD4 + and CD8 + T cell frequencies (Suppl. Table 1). Although the expression of CD28 and ICOS was unaltered in AD patients at the point in time of diagnosis, a stage-dependent analysis showed that the expression of CD28 on CD4 + T cells decreased from mean 44.8% in non-demented controls to 35.2% in patients with severe AD \( (p = 0.0270; \text{Fig. 2a}) \). The proportion of ICOS + CD4 + T cells declined from mean 1.5% in control persons compared to 0.9% ICOS + CD4 + T cells in the group of patients suffering from mild AD \( (p = 0.0396; \text{Fig. 2b}) \).

In MCI patients (mean 1.5% CTLA-4 + CD4 + /CD4 + ; \( p = 0.0392; \text{Fig. 2c} \)) and in patients with moderate AD (mean 1.4% CTLA-4 + CD4 + /CD4 + ; \( p = 0.0187 \)), the expression of CTLA-4 by CD4 + T cells was increased compared to non-demented controls (average 1% CTLA-4 + CD4 + / CD4 + ). No alterations of CD28, ICOS or CTLA-4 were detected in CD8 + T cells.

**Correlation between co-stimulatory molecules and AD-associated alterations in CSF**

Alterations of phospho-tau (p-tau) and Amyloid-β 1–42 within CSF belong to the core features of AD and the determination of these values are part of the routine dementia diagnostics. Correlation analyses showed an association between the frequency of CD28 + CD8 + T cells and p-tau \( (p = 0.004) \), total tau \( (p = 0.0292) \), Amyloid-β 1–40 \( (p < 0.0001) \), and the Amyloid-β ratio (Amyloid-β 1–42/1–40; \( p = 0.0338 \)) and a positive correlation between ICOS + CD8 + T cells and total tau \( (p = 0.0489) \) in AD patients (Table 2a).

A stage-dependent analysis revealed a negative correlation between CD28 + CD4 + T cells and total tau \( (p = 0.0005; \text{Table 2b}) \), between CTLA-4 + CD4 + T cells and Amyloid-β 1–40 \( (p = 0.0362) \) and Amyloid-β 1–42 \( (p = 0.0243; \text{Table 2c}) \) and between ICOS + CD4 + T cells and Amyloid-β 1–40 \( (p = 0.0194) \) and Amyloid-β 1–42 \( (p = 0.0323) \) in mild AD.

In moderate AD, CTLA-4 + CD8 + T cells are positively correlated with total tau \( (p = 0.0153) \), p-tau \( (p = 0.0277) \) and the number of CD28 + CD8 + T cells are negatively correlated with p-tau \( (p = 0.0336) \) and, like in mild AD \( (p = 0.0165) \), with Amyloid-β 1–40 \( (p = 0.0240) \). In severe AD, CTLA-4 + CD8 + T cells are positively correlated with p-tau \( (p = 0.0017; \text{Table 2c}) \).

**Correlation between co-stimulatory molecules and MMSE and Q Albumin**

With the progression of dementia, the MMSE value as indicator for cognitive function declines. Correlation analyses between the MMSE values and the investigated T cell populations ruled out a positive correlation with CD28 + CD8 + T cells \( (p = 0.0466) \) and a negative correlation with CTLA-4 + CD4 + \( (p = 0.0003) \) in severe AD, patients grouped according to the severity of symptoms in mild, moderate and severe and compared to non-demented volunteers. \*\( p < 0.05 \)
illustrating that the decline of MMSE is associated with a decrease in CD28 expressing CD8+ T cells and an increase in CTLA-positive CD4+ T cells (Table 3a).

Q Albumin is a commonly used marker to determine the integrity of the B-CSF-B. In moderate AD, rising Q Albumin values as marker for a disturbed B-CSF-B are correlated with a falling frequency of CD28+CD8+ T cells (p=0.0063). In FTD, we detected a positive correlation between CD28+CD4+ T cells (p=0.0480) and a negative correlation between ICOS+CD8+ T cells (p=0.0130) and Q Albumin (Table 3b).

**Discussion**

The aim of our present study was to evaluate alterations in the expression of the co-stimulatory molecules CD28, CTLA-4 and ICOS in CD4+ and CD8+ T cells of AD, VD and FTD patients. In addition, we correlated these cell populations with dementia-associated changes such as decreasing MMSE values as marker for the progression of the cognitive decline but also with Q Albumin.

In AD we analyzed the stage-dependent changes in T cell co-stimulatory molecules in peripheral blood with disorder-specific modifications of p-tau, Amyloid-β 1–40, Amyloid-β 1–42 concentrations and the Amyloid-β ratio in CSF.

Previous studies found on the one hand a significant reduction of naïve CD28+CD4+ T cells in AD patients [23, 24] and a decreased number of CD28+CD3+ in VD [25], on the other hand an increase in CD28+CD8+ and CD28+CD4+ T cells were observed in AD patients [26, 27]. In our study, we detected a significant decreased frequency of CD28+CD4+ T cells only in severe AD. CD28 is indispensable for the activation of naïve CD4+ and CD8+ T cells. The importance of this molecule for AD pathology is reflected by the strong negative correlation between the number of peripheral CD28+CD8+ T cells and the concentration of tau proteins and Amyloid-β in CSF of AD patients and Q Albumin in moderate AD as well as a positive correlation with MMSE in severe AD.
This illustrates that with progress of this disorder, when the concentrations of tau and Amyloid-β proteins and in particular also Q Albumin are altered and the MMSE value decreased, the number of CD28+CD8+ T cells decreased as well. This might be explainable since despite CD28 is important for T cell activation and survival, several antigen-experienced T cells lose CD28 expression. These CD28- T cells are often described as terminally differentiated memory T cells [28]. With ongoing Alzheimer’s disorder, the chronic activation of T cells specific for the self-peptide Amyloid-β also continues which might also result in increasing numbers of CD28- clonally expanded T memory cells. Our data further support recent findings in peripheral and CSF CD8+ T cells from AD patients which show a shift towards memory T cells. These cells were shown to be clonal, antigen-experienced T cells that might patrol the intrathecal space of the brain which is affected by age-related neurodegeneration [29].

To our knowledge, the expression of ICOS had not been investigated in dementia until now. ICOS is another co-stimulatory molecule which was diminished in mild AD. ICOS supports a number of distinct processes during adaptive immune responses. It promotes T-dependent antibody responses [30] and drives antibody affinity maturation in the germinal center reaction [31, 32]. ICOS is involved in T helper cell polarization and might either enhance or dampen Th1 and Th2 inflammatory responses [33, 34]. In AD, and in particular in mild AD, the expression of ICOS is positively correlated with CD28 in CD4+ and in CD8+ T cells. Since ICOS is expressed only after activation, these cells might be activated or memory T cells. However, even much stronger is the correlation between ICOS and CTLA-4.

CTLA-4 is a homolog of CD28 and binds the same ligands, but with much higher affinity. In contrast to CD28, CTLA-4 is a potent inhibitory molecule. The expression of CTLA-4 is enhanced in AD (in particular moderate stage) and FTD by CD4+ T cells in VD by CD8+ T cells.

AD patients showed a peripheral increased pro-inflammatory which is discussed to be involved in the pathogenesis of the disorder. We have shown an enhanced expression of VGF by T cells from AD patients compared to age-matched controls [35]. VGF contributes to the inflammatory response since blockade of VGF reduced the secretion of pro-inflammatory cytokines [36]. The expression of CTLA-4 might be induced to counter-regulate this immune imbalance.

Correlations between the peripheral expression of CD28, ICOS and CTLA-4 by CD4+ T cells and tau proteins and Amyloid-β in CSF were only detected in mild AD. Since both the numbers of CD4+ and CD8+ T cells were diminished in AD, one might speculate that CD4+ T cells are involved in early stages of AD, afterwards CD8+ T cells might be more important. Moreover, ICOS as well as CTLA-4 are also expressed by Treg cells. Treg cells are immunoregulatory lymphocytes which play an important role in modulating inflammation. Recently it was reported that ICOS signaling is important for the surface expression of CTLA-4, both molecules are important for the suppressive capacity of these cells [37]. In AD patients, a reduction of Treg cells was described [38] and a positive correlation between Treg in MCI and AD patients and MMSE scores

Table 3 Correlation between MMSE and Q Albumin and peripheral lymphocyte populations in AD and FTD

| Cell population | Patients’ group |
|-----------------|----------------|
|                 | Severe AD      | CTLA-4 + CD4+ |
| Pearson r       | 0.6092         | −0.8677      |
| P value (two-tailed) | 0.0466         | 0.0003       |
| P value summary | *              | ***          |
| R square        | 0.3711         | 0.7529       |

| Cell population | Patients’ group |
|-----------------|----------------|
|                 | FTD            | moderate AD   |
|                 |                | FTD           |
| Pearson r       | 0.8817         | −0.5891       |
| P value (two-tailed) | 0.0480         | 0.0063        |
| P value summary | *              | **           |
| R square        | 0.7774         | 0.3470        |
|                 |                | 0.8201        |

The correlation between MMSE and CD28+CD8+ as well as CTLA-4+CD4+ T cells in severe AD patients are shown in Table 3a. Table 3b depicts the correlation between Q Albumin and the frequency of CD28+CD4+ as well as ICOS+CD8+ T cells in moderate AD and FTD.
was found [39]. It remains to be investigated whether the differential expression of both molecules by Treg cells contributes to the defective immune response seen in AD patients.

We found also in FTD patients an enhanced frequency of peripheral CTLA-4+CD4+ T cells. Since enhanced CTLA-4 expression is associated with reduced immunoregulation and therefore inflammation, this might contribute to the inflammatory immune response widely observed in FTD patients in serum and CSF [9, 40, 41]. However, another group found a diminished number of CTLA-4-expressing CD4+T cells in FTD [42].

Like in other forms of dementia, a dysfunction of the B-CSF-B, measured by Q Albumin, is also detected in FTD [43]. Impairment of the barrier has been attributed to oxidative stress and chronic inflammation. We found that with enhanced dysfunction of the B-CSF-B, the expression of ICOS by CD8+ T cells is diminished. This might be the consequence of an inflammation-mediated dysregulation between ICOS and CTLA-4 expression.

In VD patients, the number of CD8+ T cells was reduced while the frequency of CTLA-4-expressing CD8+ T cells was enhanced. CD28 and CTLA-4 compete for binding to the B7 molecules CD80 and CD86. Both molecules are expressed by professional antigen-presenting cells and provide co-stimulation following binding of a T cell [44, 45]. However, following ligation CTLA-4 exhibits much more power. This imbalance might contribute the pathology since it was shown that CD28 superagonist reduced brain damage after ischemic stroke in mice by amplification of Treg cells. The Treg cells attenuated the inflammatory response and improved outcome after experimental stroke [46]. Moreover, a recent study detected fewer Treg cells in VD [47]. This and the enhanced CTLA-4 expression further support the importance of inflammation in VD [11].

It has to be considered as well that AD is discussed as an autoimmune disorder [48, 49]. Taking into account that the expression of costimulatory molecules was found to be altered in autoimmune disorders and is discussed as potential target for treatment [50, 51], our findings might help to find new treatment opportunities for AD patients.

There are some limitations that have to be considered. The age of our control group is significantly different from that of the AD patients, who are older. However, no differences considering age were found between the non-demented volunteers and the other dementia groups as well as between AD and FTD and VD patients. Also, no significant differences in age within the patients suffering from the three stages of AD were found. Besides it is unexplained whether the alterations within the expression of costimulatory molecules, reflecting an altered immune system, contribute to the pathology of dementia or whether these changes are rather an epigenetic phenomenon. In this context it has to be considered that changes in the immune system, in particular (neuro-) inflammation, epigenetic and genetic pathways alter neurogenesis, which was found to be altered in AD raising the opportunity for therapeutic approaches, focusing on anti-inflammatory and pro-neurogenic interventions [52].

Conclusions

The immune system in patients with several forms of dementia is differently modified. Disorder-specific alterations in the expression of co-stimulatory molecules might reflect the immune response after diverse stimuli. In AD, the stage-dependent changes in co-stimulatory molecules in T cells, combined with the correlation with AD-specific proteins, might be the consequence of a failed immune defense against these factors.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00406-021-01297-1.

Funding Open Access funding enabled and organized by Projekt DEAL.

Declarations

Conflict of interest All authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Onyike CU, Diehl-Schmid J (2013) The epidemiology of frontotemporal dementia. Int Rev Psychiatry 25:130–137
2. Raz L, Knoefel J, Bhaskar K (2016) The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 36:172–186
3. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM (2016) Alzheimer’s disease. Lancet 388:505–517
4. Wolters FJ, Ikrar MA (2019) Epidemiology of vascular dementia. Arterioscler Thromb Vasc Biol 39:1542–1549
5. Olszewska DA, Lonergan R, Fallon EM, Lynch T (2016) Genetics of frontotemporal dementia. Curr Neurol Neurosci Rep 16:107
6. Yoshiyama Y, Lee VM, Trojanowski JQ (2001) Frontotemporal dementia and tauopathy. Curr Neurol Neurosci Rep 1:413–421
7. Arata Y, Watanabe A, Motosugi R, Murakami R, Goto T, Hori S, Hirayama S, Hamazaki J, Murata S (2019) Defective induction of the proteasome associated with t-cell receptor signaling underlies t-cell senescence. Genes Cells 24:801–813
8. Chou JP, Effros RB (2013) T cell replicative senescence in senescence in human aging. Curr Pharm Des 19:1680–1698
9. Bright F, Werry EL, Dobson-Stone C, Piguet O, Ittner LM, Halliday GM, Hodges JR, Kiernan MC, Loy CT, Kassioti M, Krijl JJ (2019) Neuroinflammation in frontotemporal dementia. Nat Rev Neurol 15:540–555
10. Heppner FL, Ransohoff RM, Becher B (2015) Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci 16:358–372
11. Wang XX, Zhang B, Xia R, Jia QY (2020) Inflammation, apoptosis and autophagy as critical players in vascular dementia. Eur Rev Med Pharmacol Sci 24:9601–9614
12. Musaeus CS, Glearup HS, Hogh P, Waldemar G, Hasselbalch SG, Simonsen AH (2020) Cerebrospinal fluid/plasma albumin ratio as a biomarker for blood-brain barrier impairment across neurodegenerative dementias. J Alzheimers Dis 75:429–436
13. Ripphagen JM, Ramakers I, Freeze WM, Pagen LHG, Hanseeuw EJ, Verbeek MM, Verhey FRJ, Jacobs HIL (2020) Linking aepesilin4, blood-brain barrier dysfunction, and inflammation to Alzheimer’s pathology. Neurobiol Aging 85:96–103
14. Sharpe AH, Freeman GJ (2002) The b7-cd28 superfamily. Nat Rev Immunol 2:116–126
15. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Krammer PH, Leiden JM, June CH (1989) Cd28 activation pathway regulates the production of multiple t-cell-derived lymphokines/lymphokines. Proc Natl Acad Sci USA 86:1333–1337
16. Hutloff A, Dittrich AM, Beier KC, Eljashewitz B, Kraft R, Anagnostopoulos I, Kroczek RA (1999) Icos is an inducible t-cell co-stimulator structurally and functionally related to cd28. Nature 397:263–266
17. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH (2016) Coinhibitory pathways in the b7-cd28 ligand-receptor family. Immunity 44:955–972
18. Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA (1994) Ctla-4 can inhibit t-cell proliferation in vitro in a cd4+ t cells based pathway and cytokine production in Alzheimer’s disease patients. Neurobiol Aging 6:440–453
19. Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, Horan T, Shih G, Zhang M, Coccia MA, Kohto N, Tafuri-Bladt A, Brankow D, Campbell P, Chiang D, Chiu L, Dai T, Duncan G, Elliott GS, Hui A, McCabe SM, Scully S, Shahinian A, Shaklee CL, Van G, Mak TW, Senaldi G (1999) T-cell co-stimulation through phosphoinositide 3-kinase. Proc Natl Acad Sci USA 96:10171–10176
20. Busse S, Hoffmann J, Michler E, Hartig R, Frodl T, Busse S (2017) Alternations in the peripheral immune system in dementia. J Alzheimers Dis 58:1303–1313
21. Busse S, Hoffmann J, Michler E, Hartig R, Frodl T, Busse M (2021) Dementia-associated changes of immune cell composition within the cerebrospinal fluid. Brain Behav Immun Health 106:20371–20376
22. Petersen RC (2016) Mild cognitive impairment. Continuum (Minneap Minn) 22:404–418
23. Larbi A, Pawelec G, Witkowski JM, Schipper HM, Derhovanessian E, Goldeck D, Fulop T (2009) Dramatic shifts in circulating cd4+ but not cd8+ t cell subsets in mild Alzheimer’s disease. J Alzheimer's Dis 17:91–103
24. Pellicano M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, Rubino G, Iemolo F, Candore G, Caruso C, Derhovanessian E, Pawelec G (2012) Immune profiling of alzheimer patients. J Neuroimmun 242:52–59
25. Cacabelos R, Torrellas C, Fernandez-Novoa L, Lopez-Munoz F (2016) Histamine and immune biomarkers in cns disorders. Mediators Inflamm 2016:1924603
26. Lombardi VR, Garcia M, Rey L, Cacabelos R (1999) Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer’s disease (ad) individuals. J Neuroimmun 97:163–171
27. Speciale L, Calabrese E, Sorresa M, Tinelli C, Mariani C, Sanvito L, Longhi R, Ferrante P (2007) Lymphocyte subset patterns and cytokine production in Alzheimer’s disease patients. Neurobiol Aging 28:1163–1169
28. Mou D, Espinosa J, Lo DJ, Kirk AD (2014) Cd28 negative t cells: is their loss our gain? Am J Transplant 14:2460–2466
29. Gate D, Saligrana N, Leventhal O, Yang AC, Unger MS, Middeldorp J, Chen K, Lehalibier B, Channappa D, De Los Santos MB, McBride A, Pluviance J, Elahi F, Tam GK, Kim Y, Greicius M, Wagner AD, Aigner L, Galasko DR, Davis MM, Wyss-Coray T (2020) Clonally expanded cd8+ t cells patrol the cerebrospinal fluid in Alzheimer’s disease. Nature 577:399–404
30. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA (2001) Icos co-stimulator receptor is essential for t-cell activation and function. Nature 409:97–101
31. Dong C, Temann UA, Flavell RA (2001) Cutting edge: critical role of inducible costimulator in germinal center reactions. J Immunol 166:3659–3662
32. Mak TW, Shahinian A, Yoshiyaga SK, Wakeham A, Boucher LM, Pintilie M, Duncan G, Gajewska BU, Gronski M, Eriksson U, Odermatt B, Ho A, Bouchard D, Whorisky JS, Jordana M, Ohashi PS, Pawson T, Bladt F, Tafuri A (2003) Costimulation through the inducible costimulator ligand is essential for both t helper and b cell functions in t cell-dependent b cell responses. Nat Immunol 4:765–772
33. Gigoux M, Zhang J, Pak Y, Xu M, Choe J, Mak TW, Suh WK (2009) Inducible costimulator promotes helper t-cell differentiation through phosphoinositide 3-kinase. Proc Natl Acad Sci USA 106:20371–20376
34. Lohning M, Hutloff A, Kallinich T, Mages HW, Bonhagen K, Radbruch A, Hamelmann E, Kroczena RA (2003) Expression of icos in vivo defines cd4+ effecter t cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J Exp Med 197:181–193
35. Busse S, Steiner J, Glorius S, Dobrowolny H, Greiner-Bohl S, Mawrin C, Bommhardt U, Hartig R, Bogerts B, Busse M (2015) Vgf expression by t lymphocytes in patients with Alzheimer’s disease. Oncotarget 6:14843–14851
36. Busse S, Steiner J, Micheil J, Dobrowolny H, Mawrin C, Krause TJ, Adamszak M, Bogerts B, Bommhardt U, Hartig R, Busse M (2014) Age-related increase of vgf-expression in t lymphocytes. Aging 6:440–453
37. Zheng J, Chan PL, Liu Y, Qin G, Xiang Z, Lam KT, Lewis DB, Lau YL, Tu W (2013) Icos regulates the generation and function of human cd4+ treg in a ctla-4 dependent manner. PLoS ONE 8:e62203
38. Ciccocioppo F, Lanuti P, Pierdomenico L, Simeone P, Bologna G, Ercolino E, Buttari F, Fantozzi R, Thomas A, Onofri M, Centonze D, Miscia S, Marchisio M (2019) The characterization of regulatory t-cell profiles in Alzheimer’s disease and multiple sclerosis. Sci Rep 9:8788
39. Fu J, Duan J, Mo J, Xiao H, Huang Y, Chen W, Xiang S, Yang F, Chen Y, Xu S (2020) Mild cognitive impairment patients have higher regulatory t-cell proportions compared with Alzheimer’s disease-related dementia patients. Front Aging Neurosci 12:624304
40. Bossu P, Salani F, Alberici A, Archetti S, Bellelli G, Galimberti D, Scarpini E, Spalletta G, Caltagirone C, Padovani A, Borroni B (2011) Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients. J Neuroinflammation 8:65
41. Gibbons L, Rollinson S, Thompson JC, Robinson A, Davidson YS, Richardson A, Neary D, Pickering-Brown SM, Snowden JS, Mann DM (2015) Plasma levels of progranulin and interleukin-6 in frontotemporal lobar degeneration. Neurobiol Aging 36(1603):e1601-1604
42. Santos RR, Torres KC, Lima GS, Fiamoncini CM, Mapa FC, Pereira PA, Rezende VB, Martins LC, Bicalho MA, Moraes EN, Reis HJ, Teixeira AL, Romano-Silva MA (2014) Reduced frequency of T lymphocytes expressing CTLA-4 in frontotemporal dementia compared to Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 48:1–5
43. Janelidze S, Hertz J, Nagga K, Nilsson K, Nilsson C, Swedish Bio FSG, Wennstrom M, van Westen D, Blennow K, Zetterberg H, Hansson O (2017) Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or apoE genotype. Neurobiol Aging 51:104–112
44. Busse S, Steiner J, Alter J, Dobrowolny H, Mawrin C, Bogerts B, Hartig R, Busse M (2015) Expression of HLA-DR, CD80, and CD86 in healthy aging and Alzheimer’s disease. J Alzheimers Dis 47:177–184
45. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, Baker J, Jeffery LE, Kaur S, Briggs Z, Hou TZ, Futter CE, Anderson G, Walker LS, Sansom DM (2011) Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (New York NY) 332:600–603
46. Na SY, Mracsko E, Liesz A, Hunig T, Veltkamp R (2014) Amplification of regulatory T cells using a CD28 superagonist reduces brain damage after ischemic stroke in mice. Stroke 46:212–220
47. D’Angelo C, Goldeck D, Pawelec G, Gaspari L, Di Iorio A, Paganelli R (2020) Exploratory study on immune phenotypes in Alzheimer’s disease and vascular dementia. Eur J Neurol 27:1887–1894
48. D’Andrea MR (2005) Add Alzheimer’s disease to the list of autoimmune diseases. Med Hypotheses 64:458–463
49. Lehrer S, Rheinstein PH (2015) Is Alzheimer’s disease autoimmune inflammation of the brain that can be treated with nasal non-steroidal anti-inflammatory drugs? Am J Alzheimers Dis Other Dement 30:225–227
50. Stuart RW, Racke MK (2002) Targeting T cell costimulation in autoimmune disease. Expert Opin Ther Targets 6:275–289
51. Vogel I, Kasran A, Cremer J, Kim YJ, Boon L, Van Gool SW, Ceuppens JL (2015) CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity. Eur J Immunol 45:1832–1841
52. Sung PS, Lin PY, Liu CH, Su HC, Tsai KJ (2020) Neuroinflammation and neurogenesis in Alzheimer’s disease and potential therapeutic approaches. Int J Mol Sci 21:701